Summary
- Closed for EoI
- Profile Type
- Research & Development Request
- POD Reference
- RDRIT20250218014
- Term of Validity
- 18 February 2025 - 18 February 2026
- Company's Country
- Italy
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
-
An Italian digital health university spin-off, is seeking research and industrial partners to develop a project focused on personalized oncology through a computational platform integrating Virtual Reality (VR), Augmented Reality (AR), and biomathematical modeling.
Call: Innovative Health Initiative or any applicable EU call.
Role sought: Research institutions, clinical partners, software developers, and commercialization specialists. - Full Description
-
Founded in 2023 in the Southern Italy, the university spin-off is specialized in digital health innovations. The team includes experts in engineering modeling, biomedical computing, and oncology. The company is working on a project and has developed a prototype available for demonstration (TRL 7-8).
Project Scope:
CancerMate leverages deterministic biomathematical models, viable for machine learning optimization) to predict tumor behavior and treatment outcomes. It enables oncologists to run simulations on patient-specific digital twins, enhancing personalized medicine.
CancerMate predicts tumor evolution and therapy response based on diagnostic images, assisting oncologists, surgeons, and pharmaceutical researchers. The project seeks partners with expertise in medical software validation, regulatory compliance (MDR 2017/745), and commercialization strategies.
Why We Seek Partners:
We aim to strengthen the regulatory, technological, and market positioning of CancerMate. We seek collaboration in:
1. Medical Software Certification: Ensuring MDR 2017/745 compliance and CE marking.
2. Clinical Validation: Expanding trials in hospitals to refine predictive accuracy.
3. Commercialization & Market Access: Engaging with pharma companies and medical imaging manufacturers.
4. Technology Development: Enhancing AI models, cloud integration, and multi-platform deployment.
Expected Collaboration:
• Research institutions: clinical trials, biomathematical modeling
• Hospitals/Oncology Centers: patient data validation, real-world testing
• Software companies: medical software development, AI implementation
• Industry partners: pharma companies, medical imaging tech firms
Call: Innovative Health Initiative or any applicable EU call
Coordinator: company does not exclude being the coordinator, but it would like to discuss this with the partnership and decide the project coordinator collegially. - Advantages and Innovations
-
• Personalized Cancer Treatment: CancerMate optimizes therapy selection, reducing costs and improving patient outcomes.
• Integration of Cutting-Edge Technologies: Combines VR/AR with biomathematical models for an immersive, precise simulation of tumor growth and treatment effects.
• Market Impact: Targets hospitals, pharmaceutical industries, and medical imaging manufacturers, enhancing decision-making and efficiency.
• Cost Reduction: Potential to decrease treatment costs by 30% in specific cases (e.g., breast cancer surgery avoidance through therapy optimization).
• Regulatory Readiness: Classified as “Class I – self-certified” under MDR 2017/745, making it easy to market. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR applied but not yet granted
- IPR notes
- Commercial licensing model: Users will access the software via a cloud-based subscription model.
Partner Sought
- Expected Role of a Partner
-
✔ Research institutions (clinical trials, regulatory validation)
✔ Hospitals/Oncology centers (real-world testing)
✔ Medical software developers (AI, cloud computing)
✔ Pharmaceutical companies (drug testing and optimization)
✔ Investors/Commercialization experts (market access strategies) - Type and Size of Partner
- SME 50 - 249
- University
- Big company
- R&D Institution
- SME 11-49
- SME <=10
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Health
- Call title and identifier
-
Innovative Health Initiative or any applicable EU call
- Coordinator required
-
Yes
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
144
- Project title and acronym
-
CancerMate - Innovative Computational tool for personalized oncology
- Health
Dissemination
- Technology keywords
- 06001013 - Medical Technology / Biomedical Engineering
- 06001005 - Diagnostics, Diagnosis
- 06001003 - Cytology, Cancerology, Oncology
- Market keywords
- 05002005 - Other medical imaging
- 05003001 - Therapeutic services
- Targeted countries
- All countries